Last Updated: 29/01/2025
Defining drug resistance pathways in the malaria parasite
Objectives
Taking advantage of the advances in genetic tools, this project focus on the malaria parasite molecular factors that mediate resistance to antimalarial drugs and the parasite physiological changes and biological processes behind drug exposure, opening new avenues toward the design of novel, specific and more effective malaria therapeutics.
Hampering malaria control and elimination efforts is the resilient capacity of the parasite Plasmodium falciparum to develop resistance, including resistance to the presently recommended artemisinin based combination therapy (ACT). Unraveling the mechanisms of drug resistance becomes thus of utmost importance to avoid a devastating spread and shed light for future treatment improvement.
Article: Chloroquine-susceptible and -resistant Plasmodium falciparum strains survive high chloroquine concentrations by becoming dormant but are eliminated by prolonged exposureArticle: Plasmodium falciparum Drug Resistance Genes pfmdr1 and pfcrt In Vivo Co-Expression During Artemether-Lumefantrine TherapyArticle: Expansion of a Specific Plasmodium falciparum PfMDR1 Haplotype in Southeast Asia with Increased Substrate Transport
Jul 2021 — Jun 2027
Related Resources
